Covishield

Latest news and video coverage curated from trusted media outlets

You Might Like

Supreme Court bins pleas for probe into Covid jab side-effects The Supreme Court dismissed a PIL seeking an investigation into alleged side effects of the Covishield vaccine, developed by AstraZeneca and Oxford and produced by Serum Institute of India. The.. IndiaTimes - Published on October 14, 2024
1 in 3 Covaxin recipients hit by adverse events: Study Nearly one-third of Covaxin recipients experienced adverse events of special interest within a year, including respiratory, skin, and musculoskeletal issues. The study also highlighted menstrual.. IndiaTimes - Published on May 16, 2024
Kin claim deaths due to Covishield, to sue Serum Institute of India Parents sue Covishield maker over side-effects deaths, halted production due to reduced demand post high vaccination rates. Legal action in Supreme Court confirmed vaccine as the cause of deaths. IndiaTimes - Published on May 12, 2024
Covishield side effects: Doctors' group urges govt to review all Covid vaccines IndiaTimes - Published on May 10, 2024
TOI Health News Morning Briefing SII ceased Covishield production due to decreased demand, focusing on Thrombosis transparency. Car cabin air contains carcinogens, impacting health. Vitamin D absorption hindered by various factors... IndiaTimes - Published on May 10, 2024
Covishield side effects disclosed in packaging: SII Serum Institute of India stopped Covishield production due to reduced demand post high vaccination rates. They disclosed rare side effects like Thrombosis with thrombocytopenia syndrome since 2021,.. IndiaTimes - Published on May 9, 2024
Stopped producing Covishield in Dec 2021: SII after AstraZeneca recall UK-based drug major AstraZeneca's decision to withdraw its Covid-19 vaccine globally, days after admitting to side effects, prompted Serum Institute of India to disclose that it had stopped.. IndiaTimes - Published on May 8, 2024
'Manufacturing of Covishield ceased two years back due to poor demand' IndiaTimes - Published on May 8, 2024
SII stopped manufacturing Covishield since December 2021, says 'disclosed side effects details in packaging insert' SII stopped Covishield extra doses due to lawsuit, disclosed rare Thrombosis. Advocates govt collaboration. AstraZeneca withdraws Vaxzevria marketing authorisations globally. European Medicines Agency.. IndiaTimes - Published on May 8, 2024
Covishield Maker AstraZeneca Withdraws Covid-19 Vaccine Globally, Cites `Commercial Reason` According to AstraZeneca, the vaccination has been replaced by revised shots that address novel variations.  Zee News - Published on May 8, 2024Also reported by •DNA
AstraZeneca withdraws COVID vaccine worldwide AstraZeneca withdraws COVID vaccine worldwide due to TTS. Facing 100 million pound lawsuit. TTS involves blood clots, low platelets. Symptoms: severe headache, abdominal pain. Treatment: anticoagulant.. IndiaTimes - Published on May 8, 2024
Did you know Shreyas's heart stopped for 10 mins? Recent concerns regarding potential links between the Covishield vaccine and blood clots have sparked widespread discussion. Amidst this, Bollywood actor Shreyas Talpade shared his perspective, drawing.. IndiaTimes - Published on May 6, 2024
Bharat Biotech stresses on Covaxin’s safety record after AstraZeneca admits to Covishield causing rare clotting side effects Following AstraZeneca's acknowledgment in a UK court that its Covid-19 vaccine triggered a rare side effect—Thrombosis with Thrombocytopenia Syndrome (TTS), Hyderabad-based vaccine manufacturer.. IndiaTimes - Published on May 2, 2024	What is Covishield's rare side effect, TTS? Prominent vaccine manufacturer Astra Zeneca acknowledged in a court filing that TTS, a disorder that can result in blood clots and low platelet counts, can be brought on by the Covid vaccination. Many.. IndiaTimes - Published on May 2, 2024
AstraZeneca admits Covishield vaccines raises rare side-effects risk. How worried should you be? In India, almost 90% of people who received Covid vaccine, received the AstraZeneca vaccine which in India is called Covishield. DNA - Published on May 1, 2024	AstraZeneca reaffirms COVID-19 vaccine Covishield safety amidst rare side effect concerns In light of recent concerns surrounding potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical giant has reiterated its commitment to patient safety while.. DNA - Published on May 1, 2024
AstraZeneca admits its COVID-19 vaccine Covishield can cause rare... Covishield was developed by AstraZeneca in collaboration with the Oxford University during the COVID-19 pandemic DNA - Published on April 30, 2024Also reported by •IndiaTimes	Meet Pune's richest man with net worth of Rs 166500 crore, is founder of world's largest pharmaceutical company, he is.. He played a crucial role as the leader of the Serum Institute of India in the large-scale production of the Covishield vaccine amid the Covid-19 pandemic. DNA - Published on January 12, 2024
Take down defamatory posts on Covishield: Bombay high court IndiaTimes - Published on June 6, 2023	Bombay HC says content posted against Covishield vaccine prima facie defamatory The Bombay High Court on Monday said content posted by two individuals and their organisations against vaccine manufacturing major Serum Institute of India (SII) was "prima facie defamatory" and.. Mid-Day - Published on June 5, 2023
Content posted against Serum Institute of India, its Covishield vaccine prima facie defamatory: Bombay HC The Bombay high court on Monday said content posted by two individuals and their organisations against vaccine manufacturing major Serum Institute of India (SII) was "prima facie defamatory" and.. IndiaTimes - Published on June 5, 2023Also reported by •Mid-Day	SII to restart vaccine production amid surge in Covid cases Serum Institute of India CEO Adar Poonawalla told TOI on Wednesday that the company has resumed production of its Covid-19 vaccine, Covishield, in response to the increasing number of SARS-CoV-2 virus.. IndiaTimes - Published on April 12, 2023
Serum Institute of India restarts manufacturing of Covid-19 vaccine Covishield Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of Covid-19 vaccine Covishield amid rising numbers of cases of the virus infection. He said the.. IndiaTimes - Published on April 12, 2023	Record Breaking 'Hero' Gives Maximum Vaccine Doses, on Track to Beat the Pandemic *India Book of Records* strives to be a valuable resource of inspiration for people around the country, as it celebrates and honours the incredible feats and accomplishments of people in various fields.. NewsVoir - Published on April 11, 2023
Covid jab Covovax as heterologous booster to be available on CoWIN soon; to cost Rs 225 per dose Covovax can be administered to those who have already vaccinated with Covishield or Covaxin. The Drugs Controller General of India (DCGI) on January 16 had approved the market authorisation for Covovax.. IndiaTimes - Published on April 10, 2023	Booster dose of Covishield offers best immune response: Lancet study IndiaTimes - Published on January 25, 2023
Serum Institute seeks inclusion of Covid jab Covovax in CoWIN portal as heterologous booster dose for adults Covid-19 vaccine India: The Drug Controller General of India (DCGI) on January 16 approved market authorisation for Covovax as a heterologous booster dose for adults who have been administered two.. Zee News - Published on January 18, 2023	UP gets fresh supply for Covishield vax doses newKerala.com - Published on January 18, 2023
Covid-19: Govt admits multiple side-effects of coronavirus vaccines in RTI reply In the reply to an RTI filed by a Pune businessman, ICMR and CDSCO have admitted to multiple side effects of Covid-19 vaccination and the Covishield which was among the first vaccines approved by.. Zee News - Published on January 16, 2023	Do you need 4th dose of COVID vaccine? The study was conducted on the participants who had received the booster dose of the Covishield vaccination. IndiaTimes - Published on January 13, 2023
Drug panel favours nod for Covovax as Covid booster An expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India’s Covid vaccine, Covovax, as a heterologous booster dose for adults who have.. IndiaTimes - Published on January 12, 2023	Covovax may get approval as heterologous booster The government may decide on allowing Serum Institute of India’s (SII) Covovax as a heterologous booster dose, meaning it can be used for people who have taken either Covishield or Covaxin for.. IndiaTimes - Published on January 10, 2023
Covid-19: Covovax to get approval as booster in 10-15 days, says SII CEO Adar Poonawalla Serum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works very well against the.. IndiaTimes - Published on January 8, 2023	Himachal seeks 10 lakh doses of Covishield newKerala.com - Published on January 5, 2023